Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer

[1]  Peter Devilee,et al.  High‐throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium , 2016, The journal of pathology. Clinical research.

[2]  A. Zetterberg,et al.  A standardized method for quantifying proliferation by Ki-67 and cyclin A immunohistochemistry in breast cancer. , 2015, Annals of diagnostic pathology.

[3]  L. Akslen,et al.  Evaluation of Ki67 Expression across Distinct Categories of Breast Cancer Specimens: A Population-Based Study of Matched Surgical Specimens, Core Needle Biopsies and Tissue Microarrays , 2014, PloS one.

[4]  P. Regitnig,et al.  Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values. , 2014, Breast.

[5]  S. Bull,et al.  Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information , 2014, Modern Pathology.

[6]  R. Bohle,et al.  Can Ki-67 Play a Role in Prediction of Breast Cancer Patients' Response to Neoadjuvant Chemotherapy? , 2014, BioMed research international.

[7]  John M S Bartlett,et al.  An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.

[8]  P. Fasching,et al.  Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer , 2013, Clinical Cancer Research.

[9]  M. Beckmann,et al.  13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus - Opinion of a German Team of Experts (Zurich 2013) , 2013, Breast Care.

[10]  L. Tafra,et al.  Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens? , 2013, Journal of the American College of Surgeons.

[11]  I. Ellis,et al.  The prognostic significance of lymphovascular invasion in invasive breast carcinoma , 2012, Cancer.

[12]  Timothy J. Mitchison,et al.  The proliferation rate paradox in antimitotic chemotherapy , 2012, Molecular biology of the cell.

[13]  Jack Cuzick,et al.  Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. , 2011, Journal of the National Cancer Institute.

[14]  J. Cuzick,et al.  Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Andrew R. Green,et al.  MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups , 2011, Breast Cancer Research and Treatment.

[16]  M. Kurosumi,et al.  Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages? , 2011, Breast cancer.

[17]  I. Ellis,et al.  Growth fraction as a predictor of response to chemotherapy in node‐negative breast cancer , 2010, International journal of cancer.

[18]  T. Nielsen,et al.  Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[20]  J. Cuzick,et al.  Prognostic Value of a Combined ER, PgR, Ki67, HER2 Immunohistochemical (IHC4) Score and Comparison with the GHI Recurrence Score – Results from TransATAC. , 2009 .

[21]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[22]  I. Ellis,et al.  Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009, Clinical Cancer Research.

[23]  A. Giobbie-Hurder,et al.  Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Kåresen,et al.  Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications , 2007, Virchows Archiv.

[25]  J. Massagué,et al.  Genetic determinants of cancer metastasis , 2007, Nature Reviews Genetics.

[26]  C. Sotiriou,et al.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients , 2007, British Journal of Cancer.

[27]  E. Paish,et al.  Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression , 2007, Histopathology.

[28]  A. Sapino,et al.  Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure , 2006, Virchows Archiv.

[29]  C Sotiriou,et al.  Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[31]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[32]  M. Heatley.  Epithelioid microgranulomas after Pentostatin therapy in hairy cell leukaemia , 2002, Histopathology.

[33]  K. Gatter,et al.  Ki67 protein: the immaculate deception? , 2002, Histopathology.

[34]  Yulian Wu,et al.  The proteasome controls the expression of a proliferation‐associated nuclear antigen Ki‐67 , 2000, Journal of cellular biochemistry.

[35]  A. Gown,et al.  Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count. , 1999, Human pathology.

[36]  A. Thor,et al.  Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Parwaresch,et al.  Monoclonal antibodies Ki‐S3 and Ki‐S5 yield new data on the ‘Ki‐67’proteins , 1996, Cell proliferation.

[38]  Johannes Gerdes,et al.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.

[39]  Clinical Implications. , 2017, Hypertension.

[40]  E. Rutgers,et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  D. Rimm,et al.  Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer , 2014, Laboratory Investigation.

[42]  B. A. Carter,et al.  Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group , 2012 .

[43]  B. A. Carter,et al.  Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer , 2012 .

[44]  M. Osborn,et al.  Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.